Letermovir Improves Real-World, 5-Year Overall Survival Among CMV Seropositive Allogeneic Hematopoietic Cell Transplant Recipients

Puntos clave

• Overall survival significantly improved among recipients taking letermovir, enhancing their long-term outlook.
• Five-year survival rates indicate a notable difference in outcomes for CMV seropositive transplant recipients.
• Observational analysis focused on patients receiving hematopoietic cell transplants for CMV management.
• These findings highlight the need for further studies to validate clinical benefits with letermovir.